News from Ambit Biosciences Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

13 Aug, 2013, 16:02 ET Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results

 Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology,...


03 Jul, 2013, 14:00 ET Ambit to Present at JMP Securities Healthcare Conference

Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that Michael Martino, president and CEO, is scheduled to present a company overview at...


26 Jun, 2013, 08:00 ET Data from Phase 2 ACE Study of Ambit's Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Presented at 18th Congress of the European Hematology Association

Ambit Biosciences Corporation (Nasdaq: AMBI) announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were...


04 Jun, 2013, 08:00 ET Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology

 Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that multiple presentations from the Phase 2 ACE study of quizartinib (AC220), a...


22 May, 2013, 08:00 ET Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology

Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective...


16 May, 2013, 08:00 ET Ambit Biosciences Announces Pricing of Initial Public Offering

 Ambit Biosciences Corporation today announced the pricing of its initial public offering of 8,125,000 shares of its common stock at $8.00 per...


15 Apr, 2013, 08:00 ET Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors

 Ambit Biosciences Corporation today announced that David R. Parkinson, M.D., has been appointed to the company's board of directors. Dr....


11 Mar, 2013, 22:00 ET Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors

 Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for...


20 Feb, 2013, 16:01 ET Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering

Ambit Biosciences Corporation today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...


20 Dec, 2010, 16:01 ET Ambit Biosciences Initiates Two Phase I Clinical Trials

Ambit Biosciences (Ambit), today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2)...


08 Nov, 2010, 08:15 ET Ambit Biosciences Strengthens Board of Directors and Executive Team

Ambit Biosciences Corporation (Ambit) today announced the strengthening of its Board and management team.   "The Board is delighted to...


05 Nov, 2010, 21:25 ET Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering

Ambit Biosciences Corporation (“Ambit”), announced today that it has filed a registration statement with the Securities and Exchange...


26 Jul, 2010, 08:00 ET Ambit Biosciences Announces Transition in Company Leadership

Ambit Biosciences Corporation (Ambit), a recognized global leader in kinase drug discovery and development, announced today that its Board of...


24 Nov, 2009, 11:30 ET Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3...


02 Apr, 2002, 00:00 ET Ambit Biosciences and AstraZeneca Enter Proteomics Based Research Collaboration

SAN DIEGO, April 2 /PRNewswire/ -- Ambit Biosciences Corporation, a privately held drug discovery and development company, today announced a...